Bioresorbable Vascular Scaffold Market Size, Share, Growth, and Industry Analysis, By Type (Metal BVS,Polymer BVS), By Application (Hospital & Clinic,Medical Center), Regional Insights and Forecast to 2035

Bioresorbable Vascular Scaffold (BVS) Market Overview

The global Bioresorbable Vascular Scaffold Market is forecast to expand from USD 335.14 million in 2026 to USD 376.7 million in 2027, and is expected to reach USD 968.6 million by 2035, growing at a CAGR of 12.4% over the forecast period.

The global bioresorbable vascular scaffold (BVS) market was valued at approximately USD 161.5 million in 2022 and expanded to around USD 399.44 million by 2023, demonstrating a resurgence after earlier market stagnation. The renewed focus on bioresorbable stents—especially for coronary artery disease (CAD) and peripheral artery disease (PAD)—reflects strong clinical and regulatory interest in next-generation scaffold designs. In 2024, the FDA approval of Abbott’s Esprit BTK scaffold marked a breakthrough in below-the-knee (BTK) indications, opening a new frontier for vascular restoration therapies.

The U.S. market dominates global BVS adoption, representing approximately 81% of total market value in 2023. Advanced interventional infrastructure and a concentration of leading clinical trials position the U.S. as the global hub for innovation. By 2024, multiple U.S. centers began enrolling patients in new BVS trials—covering ~264 subjects across 60 international sites. Overall, North America holds roughly 50–55% of global BVS usage, with Europe and Asia-Pacific emerging as strong contributors.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 47% of clinicians cite the increasing prevalence of CAD and PAD as the primary factor driving BVS demand.
• Major Market Restraint: 33% of procurement committees report safety and thrombosis risk as main deterrents.
• Emerging Trends: 25% of new scaffold pipelines use magnesium alloy or composite materials.
• Regional Leadership: North America leads with approximately 50–55% of total BVS usage.
• Competitive Landscape: The top 3 companies control nearly 60% of the U.S. market share.
• Market Segmentation: Drug-eluting BVS devices represent roughly 70% of total deployed scaffolds.
• Recent Development: IDE approvals for new BVS devices increased by 22% in 2024.

Bioresorbable Vascular Scaffold Market Latest Trends

The Bioresorbable Vascular Scaffold Market is rapidly advancing through innovations in thinner strut architecture, high-molecular-weight polymers, and magnesium-based alloys. In 2025, R3 Vascular’s MAGNITUDE scaffold received FDA IDE approval to begin enrollment of 264 subjects across 60 sites worldwide. This device uses ultra-high molecular weight polylactic acid and features reduced strut thickness for improved vascular flow dynamics. Next-generation magnesium scaffolds demonstrate rapid degradation, losing approximately 40% of mass in the first 90 days and about 95% within one year, achieving optimal vessel restoration timelines.

The revival of clinical confidence in BVS is largely due to enhanced mechanical strength, radiopacity, and improved resorption kinetics. Drug-eluting scaffolds dominate modern pipelines—about 70% of all BVS devices deployed in 2024 include antiproliferative drug coatings such as everolimus or sirolimus. In Europe, BVS market value reached USD 93.6 million in 2023, while Japan and South Korea are leading R&D and export centers in Asia. Current Bioresorbable Vascular Scaffold Market Trends highlight expansion beyond coronary uses into peripheral vascular applications (e.g., PAD and BTK), with design emphasis on safety, deliverability, and precision imaging guidance.

Bioresorbable Vascular Scaffold Market Dynamics

DRIVER

"Rising Burden of Coronary Artery and Peripheral Artery Diseases"

Globally, cardiovascular disease accounts for approximately 20.5 million deaths annually. Rising prevalence of CAD and PAD has increased demand for temporary, bioresorbable scaffolds that restore vessel compliance post-procedure. Over 200,000 lower-limb revascularization procedures occur yearly in developed regions, and permanent metallic stents often pose long-term complications. Bioresorbable scaffolds offer a more physiological alternative by maintaining luminal support during healing and gradually dissolving thereafter. The FDA’s 2024 clearance of Abbott’s Esprit BTK scaffold exemplifies the growing clinical and regulatory support for these innovations.

RESTRAINT

"Safety Concerns and Thrombosis Risk in Complex Lesions"

Earlier BVS iterations, such as the Absorb system, were withdrawn after reports of elevated thrombosis rates in small-diameter or long-lesion vessels. Strut thickness exceeding 150 microns impaired endothelialization, leading to mechanical instability. Although newer systems now feature thinner struts (≤95 microns), lingering safety perceptions persist among interventional cardiologists. Regulatory trials typically span 3–5 years to confirm long-term efficacy, raising both cost and capital risks. In procurement surveys, 33% of decision-makers listed unresolved safety data as their top concern. Additionally, mechanical durability remains a technical challenge in calcified or tortuous arteries, limiting immediate mainstream adoption.

OPPORTUNITY

"Peripheral Vascular Applications and Advanced Materials"

Opportunities are emerging in the below-the-knee (BTK) and femoropopliteal segments, where existing metal stents or balloons underperform. The MAGNITUDE trial, encompassing 264 subjects across 60 centers, represents a key step toward expanding peripheral use cases. Magnesium-based scaffolds that degrade within 12 months enable vessel restoration without permanent foreign material. Hybrid systems—combining polymer and metallic cores—offer increased radial force and flexibility. Approximately 15% of new scaffold trials globally integrate intravascular imaging or AI guidance for precision deployment. Emerging markets such as China and India currently have scaffold penetration rates below 5% of Western levels, representing substantial untapped opportunity.

CHALLENGE

"Trial Burden, Reimbursement Gaps, and Cost Pressures"

Active BVS devices require extensive clinical validation, often involving randomized controlled trials spanning several years. In 2024, IDE trial approvals increased by 22% year-over-year, signaling both innovation and regulatory hurdles. Manufacturing costs are high—cleanroom polymer processing and drug coating elevate unit cost by 2–4× relative to metallic stents. Many insurers reimburse BVS under generic stent codes, reducing profit margins. In roughly 15% of surveyed cath labs, clinicians postponed BVS adoption pending long-term outcome data. Material supply constraints also persist—about 20% of production delays arise from magnesium alloy sourcing issues. These financial and logistical challenges shape the path of future BVS market scaling.

Bioresorbable Vascular Scaffold Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Metal BVS (Magnesium Alloy): These scaffolds demonstrate rapid degradation—typically losing ~40% mass within the first 90 days and ~95% within one year. Their superior radial strength makes them suitable for peripheral and infrapopliteal lesions. Magnesium-based BVS are also gaining popularity for their biocompatibility and reduced inflammatory response.

The metal BVS (bioresorbable vascular scaffold) segment is forecast to be worth USD 120 million in 2025, representing roughly 40% share, and is projected to reach USD 345 million by 2034, expanding at a CAGR of ~12.1%. This growth is driven by the increasing use of magnesium and zinc-based alloys that provide superior mechanical strength and predictable degradation timelines compared to polymer scaffolds. The segment benefits from continuous clinical validation, enhanced biocompatibility, and a growing number of product approvals for next-generation metal scaffolds designed to improve arterial healing and long-term safety outcomes.

Top 5 Major Dominant Countries in the Metal BVS Segment

• United States: ~USD 40 million, ~33.3% share of metal BVS, CAGR ~11.8%. The U.S. dominates due to strong clinical trial activity, regulatory support, and technological innovation in magnesium-based vascular scaffolds.

• Germany: ~USD 15 million, ~12.5% share, CAGR ~12.0%. Growing research partnerships and government-backed funding for bioresorbable cardiovascular implants support consistent market expansion.

• Japan: ~USD 14 million, ~11.7% share, CAGR ~12.3%. Advanced healthcare systems and early adoption of high-precision medical alloys contribute to strong product demand.

• United Kingdom: ~USD 10 million, ~8.3% share, CAGR ~12.2%. Increasing clinical acceptance of temporary metal scaffolds for coronary revascularization boosts the segment’s market penetration.

• China: ~USD 8 million, ~6.7% share, CAGR ~12.5%. Rapid advancements in local cardiovascular device manufacturing and growing interventional cardiology capabilities drive segment acceleration.

Polymer BVS (PLLA / UHMPLA): Polymer-based scaffolds remain the dominant class, representing over 70% of pipeline devices. Using ultra-high molecular weight polymers and thinner struts (~95 microns), these systems degrade gradually over 2–4 years, allowing full vessel remodeling. Many next-generation coronary scaffolds adopt drug-eluting polymer platforms for optimized healing.

The polymer BVS segment is estimated at USD 178.16 million in 2025, accounting for about 60% share, and is expected to reach USD 516.74 million by 2034, registering a CAGR of ~12.7%. The segment leads the market due to extensive clinical use of polylactic acid (PLA) and polycarbonate-based scaffolds that completely dissolve after vessel healing. Improved polymer chemistry, reduced strut thickness, and enhanced drug-eluting coatings are supporting higher adoption among cardiologists aiming for safer, temporary vessel support. Moreover, growing preference for polymer scaffolds in emerging economies due to cost efficiency and biodegradability is fueling global expansion.

Top 5 Major Dominant Countries in the Polymer BVS Segment

• United States: ~USD 65 million, ~36.5% share of polymer BVS, CAGR ~12.4%. The U.S. remains the innovation hub, driven by strong R&D investment and advanced clinical trials of next-gen polymer scaffolds.

• Germany: ~USD 20 million, ~11.2% share, CAGR ~12.6%. Favorable regulatory approvals and extensive use in interventional cardiology centers reinforce its regional leadership.

• Japan: ~USD 18 million, ~10.1% share, CAGR ~12.3%. Increased use of bioresorbable polymer stents in minimally invasive procedures boosts consistent market adoption.

• China: ~USD 15 million, ~8.4% share, CAGR ~13.0%. Rapid domestic production advancements and increasing coronary procedure volumes contribute to strong growth potential.

• United Kingdom: ~USD 12 million, ~6.7% share, CAGR ~12.5%. Expansion of cardiovascular care facilities and early clinician adoption of polymer-based scaffolds underpin stable growth.

BY APPLICATION

Hospitals and Catheterization Labs: Account for approximately 80% of scaffold implantations worldwide. These facilities possess the imaging and interventional infrastructure necessary for complex deployments.

The hospital & clinic segment is valued at USD 210 million in 2025, representing approximately 70% share of the total market, and is projected to grow to USD 605 million by 2034, expanding at a CAGR of ~12.3%. Hospitals and clinics dominate global demand due to the high prevalence of coronary artery disease and the concentration of interventional cardiology procedures within specialized cardiovascular units. Increasing preference for bioresorbable scaffolds in complex stenting cases, driven by enhanced post-implantation imaging and improved long-term vessel recovery, continues to fuel hospital-based adoption globally.

Top 5 Major Dominant Countries in Hospital & Clinic Application

• United States: ~USD 70 million, ~33.3% share, CAGR ~12.1%. Strong penetration of BVS in tertiary cardiac centers, coupled with frequent clinical trials, underpins sustained growth in interventional procedures.

• Germany: ~USD 25 million, ~11.9% share, CAGR ~12.4%. Large-scale hospital networks and access to reimbursement programs accelerate adoption of next-generation biodegradable vascular scaffolds.

• Japan: ~USD 20 million, ~9.5% share, CAGR ~12.2%. Increasing utilization of polymer and magnesium scaffolds within university hospitals and cardiac institutes strengthens market expansion.

• China: ~USD 18 million, ~8.6% share, CAGR ~12.7%. Rapid healthcare infrastructure modernization and growing cardiovascular procedure volumes bolster demand for advanced BVS devices.

• United Kingdom: ~USD 15 million, ~7.1% share, CAGR ~12.3%. Expansion of coronary care units and rising government focus on minimally invasive procedures support segment advancement.

Medical Center (Specialty Vascular & Peripheral Centers): Dedicated vascular centers and peripheral intervention clinics represent ~20 % of BVS use, especially for PAD/BTK adoption in specialty centers with imaging and device support

The medical center segment is projected at USD 88.16 million in 2025, representing 30% share, and is expected to reach USD 256.74 million by 2034, growing at a CAGR of ~12.6%. Specialized cardiac and interventional centers increasingly favor bioresorbable scaffolds for younger patients and complex vascular lesions requiring short-term vessel support. Ongoing innovation in polymer and hybrid BVS designs and increasing physician training in non-permanent scaffold usage are expected to further elevate adoption in standalone cardiac centers.

Top 5 Major Dominant Countries in Medical Center Application

• United States: ~USD 30 million, ~34.0% share, CAGR ~12.4%. Growth driven by expanding network of cardiac specialty centers and strong clinician confidence in new-generation resorbable scaffolds.

• Germany: ~USD 10 million, ~11.3% share, CAGR ~12.6%. Technological advancements and rising collaborations between device makers and heart institutes foster increased utilization.

• Japan: ~USD 8 million, ~9.1% share, CAGR ~12.3%. Demand supported by high procedure precision, improved post-procedure vessel visualization, and better training programs in scaffold deployment.

• China: ~USD 7 million, ~8.0% share, CAGR ~13.0%. Rapid establishment of private interventional centers and favorable device localization policies spur high growth potential.

• United Kingdom: ~USD 5 million, ~5.7% share, CAGR ~12.5%. Focus on specialized care and increased procedural safety standards enhance the usage of bioresorbable vascular scaffolds in advanced cardiac centers.

Bioresorbable Vascular Scaffold Market Regional Outlook

Regionally, North America leads the global BVS market with 50–55% of total share, followed by Europe (20–25%), Asia-Pacific (15–20%), and Middle East & Africa (5–10%). Market expansion in APAC and MEA regions is driven by rising cardiovascular procedure volumes and broader regulatory participation.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America dominates with approximately 50–55% of global BVS adoption. In 2023, the U.S. accounted for 81% of total global usage value, supported by over 6,000 catheter labs nationwide. The region remains the epicenter for IDE trials, such as the MAGNITUDE study. The 2024 FDA clearance of Abbott’s Esprit BTK scaffold further solidified the U.S. lead. Comprehensive reimbursement systems and strong corporate presence—particularly Abbott and Elixir—support ongoing market expansion.

The North American Bioresorbable Vascular Scaffold Market is valued at USD 110 million in 2025 and is projected to reach USD 320 million by 2034, registering a CAGR of ~12.5% and capturing around 36.8% global share. North America dominates due to advanced interventional cardiology infrastructure, strong regulatory backing for device innovation, and early adoption of bioresorbable scaffolds among physicians. Expanding clinical data on next-generation magnesium and polymer BVS supports strong market penetration across tertiary care facilities and cardiac centers.

North America – Major Dominant Countries in the “Bioresorbable Vascular Scaffold Market”

• United States: ~USD 100 million, ~90.9% share, CAGR ~12.5%. The U.S. market leads globally, fueled by extensive clinical trials, established reimbursement systems, and high adoption of FDA-approved resorbable scaffold technologies.

• Canada: ~USD 6 million, ~5.5% share, CAGR ~12.2%. Increasing governmental support for cardiovascular innovation and adoption of eco-friendly, bioresorbable devices strengthen market presence.

• Mexico: ~USD 3 million, ~2.7% share, CAGR ~12.7%. Growth supported by investments in private cardiac hospitals and government healthcare modernization initiatives.

• Puerto Rico: ~USD 1 million, ~0.9% share, CAGR ~12.1%. Adoption remains modest but rising, driven by improved access to imported cardiovascular stent technologies.

• Dominican Republic: ~USD 0.5 million, ~0.5% share, CAGR ~12.3%. Market growth aided by training programs and gradual expansion of catheterization labs in major hospitals.

EUROPE

Europe contributes 20–25% of global BVS demand, with a market value of USD 93.6 million in 2023. Coronary indications represent 84.72% of scaffold use. Germany leads Europe with 21.41% regional share, followed by the UK, France, and Italy. The CE regulatory framework facilitates product mobility across borders, while national cardiac registries in Germany and the UK ensure outcome transparency. Eastern Europe (Poland, Czech Republic) began pilot BVS programs in 2024, signaling broader adoption.

The European Bioresorbable Vascular Scaffold Market is estimated at USD 80 million in 2025, anticipated to reach USD 230 million by 2034, expanding at a CAGR of ~12.4%, representing roughly 26.8% global share. Europe’s growth is driven by rising coronary artery disease prevalence, strong cardiac device regulations, and favorable reimbursement policies across developed economies. Advancements in biodegradable metallic and polymer scaffolds, coupled with hospital-based trials in Germany, the U.K., and France, support regional market strength.

Europe – Major Dominant Countries in the “Bioresorbable Vascular Scaffold Market”

• Germany: ~USD 25 million, ~31.3% share, CAGR ~12.5%. High PCI rates and adoption of next-gen magnesium scaffolds in major hospitals secure Germany’s leadership.

• United Kingdom: ~USD 15 million, ~18.8% share, CAGR ~12.3%. Growing national emphasis on minimally invasive cardiovascular care supports increasing scaffold use.

• France: ~USD 12 million, ~15.0% share, CAGR ~12.4%. Expanding research trials and adoption in hybrid operating rooms promote consistent market development.

• Italy: ~USD 10 million, ~12.5% share, CAGR ~12.2%. Improvements in cardiovascular therapy standards and public health initiatives drive segment advancement.

• Spain: ~USD 8 million, ~10.0% share, CAGR ~12.3%. Strong focus on post-angioplasty recovery and greater hospital usage of temporary scaffold solutions underpin stable growth.

ASIA-PACIFIC

Asia-Pacific comprises 15–20% of global BVS share. Japan and South Korea serve as key R&D and manufacturing hubs, while China rapidly scales its domestic scaffold capabilities. Indian manufacturer Meril introduced the MeRes100 BVS as a local innovation milestone. Southeast Asian nations, including Singapore and Malaysia, launched pilot installations in tertiary hospitals. APAC’s rapid cardiovascular infrastructure growth—over 1,000 new cath labs expected by 2030—positions the region as a high-potential frontier for BVS expansion.

The Asian Bioresorbable Vascular Scaffold Market is projected at USD 60 million in 2025 and is forecast to reach USD 190 million by 2034, growing at a CAGR of ~13.0%, accounting for approximately 22.1% of the global market. Asia represents the fastest-growing regional hub, driven by increasing prevalence of cardiovascular disease, rapid healthcare modernization, and expansion of interventional cardiology centers. Local manufacturing of cost-efficient scaffolds and government funding for cardiac device innovation further accelerate adoption.

Asia – Major Dominant Countries in the “Bioresorbable Vascular Scaffold Market”

• China: ~USD 20 million, ~33.3% share, CAGR ~13.2%. Government-backed medical technology initiatives and expanding domestic BVS manufacturing capacity fuel strong national growth.

• Japan: ~USD 15 million, ~25.0% share, CAGR ~12.5%. Clinical preference for advanced resorbable scaffolds with high biocompatibility drives consistent procedural adoption.

• India: ~USD 10 million, ~16.7% share, CAGR ~13.5%. Rising cardiac procedure volumes and improved catheterization infrastructure stimulate robust market expansion.

• South Korea: ~USD 8 million, ~13.3% share, CAGR ~12.8%. Rapid growth supported by integration of cutting-edge vascular devices in national hospital systems.

• Australia: ~USD 4 million, ~6.7% share, CAGR ~12.3%. Strong demand from advanced cardiac care facilities and clinical trials drives steady scaffold utilization.

MIDDLE EAST & AFRICA

The MEA region accounts for 5–10% of the BVS market. GCC nations (UAE, Saudi Arabia) dominate regional adoption with over 25 active hospitals deploying scaffold systems. South Africa leads sub-Saharan usage, while Egypt and Kenya show growing interest. Import dependency remains high at ~90%, and 60% of hospitals face capital justification hurdles for procurement. Supply chain limitations persist, with 15% of shipments experiencing thermal deviations. Despite challenges, MEA’s emerging cardiovascular programs signal strong long-term potential.

The Middle East & Africa Bioresorbable Vascular Scaffold Market is estimated at USD 48.16 million in 2025, projected to reach USD 121 million by 2034, recording a CAGR of ~10.9%, accounting for about 14.3% of global share. The region’s expansion is supported by increased cardiovascular disease incidence, national investments in cardiac infrastructure, and growing availability of imported scaffold technologies. Strategic partnerships with multinational medical device firms are further aiding product distribution and clinical adoption.

Middle East & Africa – Major Dominant Countries in the “Bioresorbable Vascular Scaffold Market”

• United Arab Emirates: ~USD 12 million, ~24.9% share, CAGR ~11.0%. High investment in hospital innovation and international medical collaborations strengthen adoption rates.

• Saudi Arabia: ~USD 10 million, ~20.8% share, CAGR ~10.8%. Expansion of cardiovascular centers and national heart health programs drive consistent market advancement.

• South Africa: ~USD 8 million, ~16.6% share, CAGR ~10.7%. Increased private healthcare investment and awareness initiatives fuel incremental scaffold usage.

• Egypt: ~USD 6 million, ~12.5% share, CAGR ~10.9%. Infrastructure expansion and greater imports of advanced medical technologies support stable market growth.

• Israel: ~USD 5 million, ~10.4% share, CAGR ~10.6%. Cutting-edge R&D in bioresorbable materials and device design fosters innovation-driven expansion.

List of Top Bioresorbable Vascular Scaffold Companies

• Abbott
• Kyoto Medical
• Biotronik
• Elixir Medical

• Abbott: Holds an estimated 25–30% share globally, leading innovation in drug-eluting and peripheral scaffolds such as the Esprit and Absorb series.
• Elixir Medical: Accounts for approximately 15–20% of the global market share, focusing on advanced polymer scaffolds with FDA and CE pipeline products.

Investment Analysis and Opportunities

The Bioresorbable Vascular Scaffold Market is witnessing increasing investment activity, with more than 120 medical device companies investing in bioresorbable technologies between 2022 and 2025. Bioresorbable Vascular Scaffold Market Analysis indicates that nearly 65% of investments focus on polymer-based scaffold development, designed to fully resorb within 24 to 36 months after implantation. Around 55% of investments are directed toward clinical trials, involving more than 15,000 patients globally to evaluate safety and efficacy.

Bioresorbable Vascular Scaffold Market Opportunities highlight that approximately 50% of investments are allocated to next-generation drug-eluting scaffolds capable of reducing restenosis rates by nearly 30%. Nearly 45% of investments target emerging markets, where cardiovascular disease affects over 300 million individuals and interventional procedures exceed 20 million annually.

Additionally, about 40% of investments focus on manufacturing advancements, enabling production of more than 5 million scaffold units annually. Bioresorbable Vascular Scaffold Market Insights show that more than 80 collaborations have been formed between research institutions and device manufacturers across over 60 countries. These developments are driving Bioresorbable Vascular Scaffold Market Growth, Bioresorbable Vascular Scaffold Market Outlook, and Bioresorbable Vascular Scaffold Market Opportunities.

New Product Development

The Bioresorbable Vascular Scaffold Market is advancing rapidly, with more than 90 new scaffold designs introduced between 2023 and 2025. Bioresorbable Vascular Scaffold Market Analysis indicates that nearly 60% of new product development focuses on polymer-based scaffolds with improved radial strength exceeding 120 kPa, ensuring vessel support during the healing process. Around 55% of innovations involve drug-eluting scaffolds releasing therapeutic agents over a period of 3 to 6 months, improving patient outcomes by approximately 25%.

Bioresorbable Vascular Scaffold Market Trends show that approximately 50% of new products include thinner strut designs below 100 microns, reducing thrombosis risk by nearly 20%. Around 45% of manufacturers are developing magnesium-based scaffolds capable of resorbing within 12 to 18 months.

Bioresorbable Vascular Scaffold Market Insights reveal that more than 40% of innovations focus on imaging compatibility, enabling accurate placement using advanced imaging systems in over 70% of procedures. Additionally, nearly 35% of new developments are designed for complex coronary lesions, improving procedural success rates by approximately 30%. These advancements are strengthening Bioresorbable Vascular Scaffold Market Growth and Bioresorbable Vascular Scaffold Market Opportunities.

Five Recent Developments (2023-2025)

• In 2023, polymer-based scaffolds with resorption timelines of 24 to 36 months were introduced for coronary artery treatments.
• In early 2024, drug-eluting scaffolds releasing medication over 3 to 6 months were launched, improving patient outcomes by approximately 25%.
• In mid-2024, ultra-thin strut scaffolds below 100 microns were developed, reducing thrombosis risk by nearly 20%.
• In 2025, magnesium-based scaffolds capable of resorbing within 12 to 18 months were adopted in clinical settings.
• Another 2025 development included expansion of manufacturing capacity exceeding 5 million scaffold units annually worldwide.

Report Coverage of Bioresorbable Vascular Scaffold Market

The Bioresorbable Vascular Scaffold Market Report provides comprehensive coverage across more than 80 countries, analyzing over 100 companies and 150+ scaffold products within the Bioresorbable Vascular Scaffold Industry. The Bioresorbable Vascular Scaffold Market Analysis segments the market into polymer-based scaffolds accounting for approximately 60% share, metallic scaffolds at nearly 25%, and hybrid scaffolds contributing about 15%.

The Bioresorbable Vascular Scaffold Market Research Report evaluates applications across coronary artery disease representing nearly 70% of demand, peripheral artery disease at approximately 20%, and other cardiovascular conditions around 10%. Bioresorbable Vascular Scaffold Market Insights indicate that global cardiovascular procedures exceed 25 million annually, with more than 10 million cases involving stent or scaffold implantation.

The report also highlights performance benchmarks such as restenosis reduction by approximately 30%, thrombosis risk reduction by nearly 20%, and scaffold resorption within 12 to 36 months. Additionally, more than 65% of advanced interventional cardiology procedures utilize bioresorbable technologies, supporting Bioresorbable Vascular Scaffold Market Size, Bioresorbable Vascular Scaffold Market Share, and Bioresorbable Vascular Scaffold Market Growth.

Bioresorbable Vascular Scaffold Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 335.14 Million in 2026
Market Size Value By	USD 968.6 Million by 2035
Growth Rate	CAGR of 12.4% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Metal BVS Polymer BVS By Application : Hospital & Clinic Medical Center
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample